MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing

Genth-Zotz, Sabine; Zotz, Rainer J.; Sigmund, Martin; Hanrath, Peter; Hartmann, Dagmar; Böhm, Michael; Waagstein, Finn; Treese, Norbert; Meyer, Jürgen; Darius, Harald
June 2000
European Journal of Heart Failure;Jun2000, Vol. 2 Issue 2, p175
Academic Journal
Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II–III after 6 months of therapy with metoprolol.Methods and results:: Fifty-two patients with CHF secondary to DCM (26 patients) and CAD (26 patients) and a left ventricular ejection fraction (EF) < 40% were enrolled in the placebo-controlled study. The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day. Three patients died due to cardiogenic shock, two received placebo and one metoprolol. Eight patients did not complete the study due to non-compliance. Metoprolol significantly reduced heart rate at rest and after submaximal and maximal exercise. V̇o2-max and V̇o2-AT as well as the 6-min walk test improved significantly after metoprolol treatment. There was a significant increase in EF at rest (27.3–35.2%), submaximal (28.5–37.7%) and maximal exercise (28.7–40.9%) in the metoprolol-treated patients. No differences were found between patients with CAD and DCM. We also observed reduced left ventricular volumes.


Related Articles

  • Do Cardioselective β-Adrenoceptor Antagonists Reduce Mortality in Diabetic Patients with Congestive Heart Failure? Subramanian, Usha; Kamalesh, Masoor; Temkit, M’Hamed; Eckert, George J.; Sawada, Stephen // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 4, p231 

    Background: The relative benefits of cardioselective β-adrenoceptor antagonists (CSB) among patients with congestive heart failure (CHF) and diabetes mellitus are not firmly established. Objective: To determine whether diabetic patients with CHF accrue the same mortality benefit from CSB...

  • Relax That Heart. Gorman, Christine // Time International (South Pacific Edition);1/18/1999, Issue 3, p62 

    Focuses on the availability of new beta-blocker drugs to treat congestive heart failure and hypertension. The increased cases of congestive heart failure due to doctors' success in saving heart-attack patients and an aging population; Research which showed benefits of treating patients with...

  • Relax That Heart. Gorman, Christine // Time;1/18/1999, Vol. 153 Issue 2, p94 

    Focuses on the availability of new beta-blocker drugs to treat congestive heart failure and hypertension. The increased cases of congestive heart failure due to doctors' success in saving heart-attack patients and an aging population; Research which showed benefits of treating patients with...

  • Acute coronary syndromes without ST segment elevation. Peters, Ron J. G.; Mehta, Shamir; Yusuf, Salim // BMJ: British Medical Journal (International Edition);6/16/2007, Vol. 334 Issue 7606, p1265 

    The article presents an overview of acute coronary syndrome. A discussion of the pathology behind the syndrome, which includes a progressive accumulation of inflammatory materials and lipids, the proper classification of the syndrome, the diagnosis and management of the syndrome, which includes...

  • Health and Economic Benefits of Increased Beta-Blocker Use Following Myocardial Infarction. Phillips, Kathryn A.; Shilipak, Michael G.; Coxson, Pam; Heidenreich, Paul A.; Hunink, M. G. Myriam; Goldman, Paula A.; Williams, Lawrence W.; Weinstein, Milton C.; Goldman, Lee // JAMA: Journal of the American Medical Association;12/6/2000, Vol. 284 Issue 21, p2748 

    Reports on a study of the potential health and economic impact of increased use of beta-blockers in patients who have had myocardial infarction. Design; Setting; Main outcome measures; Results; Conclusion that increased use of beta-blockers after myocardial infarction could lead to gains in...

  • Beta-blockade and other perioperative pharmacological protectors: what is now available and efficacious? Sear, J W; Higham, H; Foex, P // BJA: The British Journal of Anaesthesia;Sep2015, Vol. 115 Issue 3, p333 

    No abstract available.

  • Acute myocardial infarction in Canada: improvement with time. Dodek, Arthur // CMAJ: Canadian Medical Association Journal;7/11/2000, Vol. 163 Issue 1, p41 

    Comments on outcome in patients with acute myocardial infarction (AMI) in Canada. Effect of beta blockers on a lower mortality risk in AMI patients; Reference to clinical trials and research such as the Survival and Ventricular Enlargement (SAVE) study; Treatment with primary coronary...

  • Beta-Blockers and CAD? Boyle, Andrew J. // Clinical Cardiology Alert;Nov2012, Vol. 31 Issue 11, p81 

    The article presents an abstract and a commentary by Andrew J. Boyle of the article "Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease," by S. Bangalore and colleagues in the October 2012 issue of "The Journal of the American Medical...

  • Changing patterns of secondary preventive medication among newly diagnosed coronary heart disease patients with diabetes in Finland: A register-based study. VEHKO, TUULIKKI; MANDERBACKA, KRISTIINA; ARFFMAN, MARTTI; SUND, REIJO; REUNANEN, ANTTI; KESKIMÄKI, ILMO // Scandinavian Journal of Public Health;May2010, Vol. 38 Issue 3, p317 

    Aims: Information on medicine use among coronary heart disease (CHD) patients with diabetes in unselected patient populations is scarce. This study examines the use of medication to prevent new cardiac events among newly diagnosed CHD patients with diabetes comparing them to patients without...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics